
Granules India Limited has informed the Exchange regarding a press release dated December 17, 2024, titled "Granules India Limited Announces FDA Approval for ADHD Treatment, Addressing Drug Shortages in the U.S.".
Filed with NSE ·

Granules India Limited has informed the Exchange regarding a press release dated December 17, 2024, titled "Granules India Limited Announces FDA Approval for ADHD Treatment, Addressing Drug Shortages in the U.S.".
6ix hasn’t read this filing yet.
Follow Granules India into a list and get an email when it puts out news.
Follow Granules India